



US 20200048371A1

(19) **United States**(12) **Patent Application Publication**  
Mills et al.(10) **Pub. No.: US 2020/0048371 A1**(43) **Pub. Date: Feb. 13, 2020**(54) **TUMOR ANTIGEN PRESENTATION  
INDUCER CONSTRUCTS AND USES  
THEREOF**(71) Applicant: **Zymeworks Inc.**, Vancouver (CA)(72) Inventors: **David M. Mills**, Seattle, WA (US);  
**Eric Escobar-Cabrera**, Burnaby (CA)(21) Appl. No.: **16/499,808**(22) PCT Filed: **Mar. 29, 2018**(86) PCT No.: **PCT/CA2018/050401**

§ 371 (c)(1),

(2) Date: **Sep. 30, 2019****Publication Classification**(51) **Int. Cl.****C07K 16/46** (2006.01)**C07K 16/28** (2006.01)**C07K 16/30** (2006.01)**C07K 16/32** (2006.01)**C12N 5/0783** (2006.01)**C12N 15/10** (2006.01)**G01N 33/50** (2006.01)**A61P 35/00** (2006.01)**A61K 35/17** (2006.01)(52) **U.S. Cl.**CPC ..... **C07K 16/468** (2013.01); **A61K 2039/505**  
(2013.01); **C07K 16/2878** (2013.01); **C07K**  
**16/28** (2013.01); **C07K 16/30** (2013.01); **C07K**  
**16/32** (2013.01); **C07K 16/2803** (2013.01);  
**C07K 16/3069** (2013.01); **C12N 5/0636**  
(2013.01); **C12N 15/1093** (2013.01); **G01N**  
**33/505** (2013.01); **A61P 35/00** (2018.01);  
**A61K 35/17** (2013.01); **C07K 2317/31**  
(2013.01); **C07K 2317/52** (2013.01); **C07K**  
**2317/522** (2013.01); **C07K 2317/55** (2013.01);  
**C07K 2317/622** (2013.01); **C12N 2502/30**  
(2013.01); **C07K 16/2851** (2013.01)

(57)

**ABSTRACT**

Provided herein are tumor-associated antigen (TAA) presentation inducer constructs comprising at least one innate stimulatory receptor (ISR)-binding construct that binds to an ISR expressed on an antigen-presenting cell (APC), and at least one TAA-binding construct that binds directly to a first TAA that is physically associated with tumor cell-derived material (TCDM) comprising one or more other TAAs. The ISR-binding construct and TAA-binding construct are linked to each other, and the TAA presentation inducer construct induces a polyclonal T cell response to the first TAA and to the one or more other TAAs. Also provided are methods of using the TAA presentation inducer constructs, for example, in the treatment of cancer.

Specification includes a Sequence Listing.

